Larry Miller, PhD has published a critical review of lorcaserin, a weight loss drug recently approved by the FDA. This review, published in the Journal of the Academy of Nutrition and Dietetics, utilized the collective results of randomized trials and the statements of an FDA Advisory Panel to conclude that the incremental benefit of lorcaserin on body weight and cardiometabolic parameters above and beyond that of lifestyle modification will likely be minimal. Link.
